Summary
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab
soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary
peritoneal, or fallopian tube cancer following 1 prior line of platinum-based
chemotherapy.